Illumina faces significant challenges from China's "unreliable entity list" and competition from Roche's new SBX technology, impacting its growth prospects. Despite a 37% stock decline since August, ...

FOSTER CITY, Calif., May 19, 2025--(BUSINESS WIRE)--Signios Biosciences ("Signios Bio"), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration ...

Illumina completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. The company is refocusing on its core DNA sequencing business, targeting high single-digit revenue growth by 2027. Q2 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Illumina said the acquisition of SomaLogic will bolster its multiomics strategy to move beyond DNA sequencing, while Standard BioTools said the turnaround sale gives it an opportunity to break even ...

Faced with a slumping stock and growing competition in the next-generation sequencing market it continues to dominate, Illumina this past week committed to delivering high single-digit revenue ...

Illumina announced today it has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, for up to $425 ...

Have you ever come across the term "NGS" in articles about cancer gene panel testing or whole-genome analysis?NGS is a technology that reads DNA base sequences in large quantities.While conventional ...

Next-generation sequencing (NGS) has moved away from expensive runs and complicated workflows into a new era where benchtop instruments prioritize sustainability, accessibility, accuracy, and speed.